The next data release will be for ALS in the 1st half 2014.
If that's positive then this is a $40 stock. The mechanism of action worked in this trial so if they can do the same in ALS then the results will be positive. It will be much easier to determine the effect in the ALS trial.
The big conundrum is whether to buy now, or whether pps will be punished to lower levels. ALS seems to offer a far better outlook. Not sure what expected revenues will be once it becomes approved. So far trials with (ALS) patients have delivered great results.